90189892AML1001
Myeloid malignancies
A Phase 1, first-in-human, dose escalation study of JNJ-90189892 for relapsed or refractory AML or MDS
Phase
Compound
JNJ-90189892
NCT identifier
NCT06651229
Enrollment
N=~100
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Diagnosed AML or high-risk MDS
- ECOG PS 0–2
- No prior or concurrent secondary malignancies
- No medical history of clinically significant pulmonary compromise
- No active CNS involvement
Study
design
Primary outcomes:
- DLTs
- AEs
Secondary outcomes:
- Serum concentration of JNJ-90189892
- ADAs
- PK
- Overall response in MDS
- CR
- TTR
- DOR
- Transfusion independence
*Not a complete list of inclusion and exclusion criteria.
ADA, antidrug antibody; AE, adverse event; AML, acute myeloid leukemia; CNS, central nervous system; CR, complete response; DLT, dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; MDS, myelodysplastic neoplasms; PK, pharmacokinetics; TTR, time to response.